Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$1.17 USD
-0.10 (-7.87%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.17 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADAP 1.17 -0.10(-7.87%)
Will ADAP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADAP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADAP
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
ADAP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for ADAP
Adaptimmune price target lowered by 50c at JonesResearch, here's why
Agilent gets FDA approval for Tecelra companion diagnostic
Buy Rating Affirmed for Adaptimmune on TECELRA’s Market Potential and FDA Approval
Adaptimmune’s TECELRA®: FDA Approval Marks Solid Tumor Breakthrough
Adaptimmune granted FDA accelerated nod for lead asset